Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence

By fostering collaboration and seamless data integration into healthcare systems, the industry is laying the groundwork for a future in which “personalized medicine” is so commonplace within clinical practice that we will just start calling it “medicine.” The post Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence appeared first on MedCity…

Read More

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease

Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…

Read More

Why are U.S. healthcare costs so high?

The Incidental Economist website has a helpful explainer video. The truth is that higher cost is due to both higher prices and more utilization of healthcare goods and services. It is not caused by any one stakeholder within the healthcare ecosystem. Reducing health care costs would require significant–and often painful–tradeoffs.

Read More